Analysis of Benign Prostatic Hyperplasia Patients' Perspective Through a Third Party-Administered Survey

OBJECTIVE - To assess patient-reported functional and quality-of-life (QoL) outcomes associated with various surgical treatments for benign prostate hyperplasia (BPH).

MATERIALS AND METHODS - An independent third-party survey was sent to all patients who underwent any surgical treatment for BPH at our institution from January 2007 through January 2013.

Overall satisfaction and urinary and sexual outcomes were evaluated using Sexual Health Inventory for Men (SHIM), International Prostate Symptoms Score (IPSS) for urinary function, and International Continence Society-Short Form (ICSmaleSF) questionnaires.

RESULTS - Four hundred and seventy-nine respondents (response rate, 55. 6%) had undergone holmium laser enucleation of the prostate (HoLEP; n=214), transurethral resection of the prostate (TURP; n=210), holmium laser ablation of the prostate (n=21), photoselective vaporization (n=18), transurethral incision of the prostate (n=9), and open simple prostatectomy (OSP; n=7). Postoperatively, SHIM scores were not different. However, total IPSS varied significantly among surgical techniques (P

CONCLUSIONS - Patients generally expressed satisfaction with various interventions for BPH. However, those who underwent HoLEP had the best outcomes.

Urology. 2015 Nov 12 [Epub ahead of print]

Haidar M Abdul-Muhsin, Mark D Tyson, Paul E Andrews, Erik P Castle, Robert G Ferrigni, Christopher E Wolter, Scott K Swanson, Ryan Y McLemore, Mitchell R Humphreys

Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona. , Department of Urology (Drs Abdul-Muhsin, Tyson, Andrews, Castle, Ferrigni, Wolter, Swanson, and Humphreys), Mayo Clinic Hospital, Phoenix, Arizona, and Biostatistics (Mr McLemore), Mayo Clinic, Scottsdale, Arizona.

PubMed